Concentration Risk: The ETF focuses almost exclusively on the genomic revolution theme, leading to a highly concentrated portfolio in a specific, often volatile, sector and a relatively small number of companies, amplifying the impact of adverse events affecting this niche.

Active Management Risk: As an actively managed ETF, its performance heavily relies on the fund manager's ability to identify winning investments and navigate market conditions, with the potential to significantly underperform passive index strategies.

Innovation & Technology Risk: Many holdings are early-stage or rely on unproven, speculative technologies within the rapidly evolving biotech and genomic sectors, carrying a high risk of technological obsolescence, regulatory setbacks, or outright failure if innovations do not materialize as expected.